Cargando…

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study

Objectives: We aimed to conduct a modelling study to estimate and predict the economic burden of AD to support the healthcare management of AD in China. Methods: The economic burden of AD was estimated with an evaluation of the prevalence of AD patients and a simulation of annual resource use and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Clay, Emilie, Zhou, Junwen, Yi, Zhan-Miao, Zhai, Suodi, Toumi, Mondher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764338/
https://www.ncbi.nlm.nih.gov/pubmed/31595183
http://dx.doi.org/10.1080/20016689.2019.1667195
_version_ 1783454359636410368
author Clay, Emilie
Zhou, Junwen
Yi, Zhan-Miao
Zhai, Suodi
Toumi, Mondher
author_facet Clay, Emilie
Zhou, Junwen
Yi, Zhan-Miao
Zhai, Suodi
Toumi, Mondher
author_sort Clay, Emilie
collection PubMed
description Objectives: We aimed to conduct a modelling study to estimate and predict the economic burden of AD to support the healthcare management of AD in China. Methods: The economic burden of AD was estimated with an evaluation of the prevalence of AD patients and a simulation of annual resource use and cost per AD patient in China using a published model. Percentage of AD patients being treated was assumed to be 5% from 2010 to 2050, with three scenarios testing the value of this parameter of 10%, 20% and 40% throughout 2020 to 2050. Results: The costs of AD were estimated to be from around 91 billion RMB in 2010 to 332 billion in 2050. Most of the current burden was related to private caregivers paid by families. With the percentage of patients being treated changing from 5% to 40%, costs were estimated to double. This was related to more hospitalisations and more use of care facilities, while the burden for families would decrease. Conclusion: A high economic burden related to AD is predicted. The burden would be driven mainly by indirect costs related to the social support of the patients. Investment in improving awareness and care of AD patients is needed and worth it.
format Online
Article
Text
id pubmed-6764338
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Routledge
record_format MEDLINE/PubMed
spelling pubmed-67643382019-10-08 Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study Clay, Emilie Zhou, Junwen Yi, Zhan-Miao Zhai, Suodi Toumi, Mondher J Mark Access Health Policy Original Research Article Objectives: We aimed to conduct a modelling study to estimate and predict the economic burden of AD to support the healthcare management of AD in China. Methods: The economic burden of AD was estimated with an evaluation of the prevalence of AD patients and a simulation of annual resource use and cost per AD patient in China using a published model. Percentage of AD patients being treated was assumed to be 5% from 2010 to 2050, with three scenarios testing the value of this parameter of 10%, 20% and 40% throughout 2020 to 2050. Results: The costs of AD were estimated to be from around 91 billion RMB in 2010 to 332 billion in 2050. Most of the current burden was related to private caregivers paid by families. With the percentage of patients being treated changing from 5% to 40%, costs were estimated to double. This was related to more hospitalisations and more use of care facilities, while the burden for families would decrease. Conclusion: A high economic burden related to AD is predicted. The burden would be driven mainly by indirect costs related to the social support of the patients. Investment in improving awareness and care of AD patients is needed and worth it. Routledge 2019-09-26 /pmc/articles/PMC6764338/ /pubmed/31595183 http://dx.doi.org/10.1080/20016689.2019.1667195 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Article
Clay, Emilie
Zhou, Junwen
Yi, Zhan-Miao
Zhai, Suodi
Toumi, Mondher
Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
title Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
title_full Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
title_fullStr Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
title_full_unstemmed Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
title_short Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
title_sort economic burden for alzheimer’s disease in china from 2010 to 2050: a modelling study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764338/
https://www.ncbi.nlm.nih.gov/pubmed/31595183
http://dx.doi.org/10.1080/20016689.2019.1667195
work_keys_str_mv AT clayemilie economicburdenforalzheimersdiseaseinchinafrom2010to2050amodellingstudy
AT zhoujunwen economicburdenforalzheimersdiseaseinchinafrom2010to2050amodellingstudy
AT yizhanmiao economicburdenforalzheimersdiseaseinchinafrom2010to2050amodellingstudy
AT zhaisuodi economicburdenforalzheimersdiseaseinchinafrom2010to2050amodellingstudy
AT toumimondher economicburdenforalzheimersdiseaseinchinafrom2010to2050amodellingstudy